Oncology M&A deals from Barclays. For many it's too early to tell, but hard to find deals that paid off significantly. Of 35 deals, there were only two deals that look good retrospectively: NVS/ECYT and SGEN/CASC. None of the top 10 deals can be viewed as lucrative imo...
The PROTAC gold rush. Investment in small-molecule protein degraders is surging, but their drawbacks, limitations and risks are becoming clear go.nature.com/3sbaWjb